Adagrasib/Cetuximab Combo Has Activity in KRAS G12C+ Locally Advanced or mCRC
Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.
Source: onclive.com
Servier Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Servier Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Servier Pharmaceuticals Today - Breaking & Trending Today
16 APRIL 2024 AT 15:00 (CEST) - Form 6-K -March 29, 2024 at 08:34 am EDT
16 APRIL 2024 AT 15:00 at Evaxion Biotech A/S, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark. AGENDA 1.Election of the chairman of the...
Source: marketscreener.com
Tibsovo Market Expected to Surge with a CAGR of Approximately 5.1% by 2030
Market OverviewTibsovo (ivosidenib) is a targeted cancer therapy developed by Agios Pharmaceuticals, Inc. It is an oral, small molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is mutated in various types of cancers, including acute myeloid leukemia (AML), cholangiocarcinoma, and glioma. Tibs...
Source: pharmiweb.com
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...
Source: prnewswire.com
Esophageal Cancer Market Expected to Surge to $1.77 Billion
Dublin, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The
Source: globenewswire.com